Please login to the form below
Regeneron
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Regeneron's Japan sales performance.
MHRA approves second COVID-19 antibody treatment
Like Regeneron/Roche antibody cocktail Ronapreve (casirivimab/imdevimab), known as REGEN-COV in the US, Xevudy (sotrovimab) is licensed to treat people with mild to moderate COVID-19 who have at
Regeneron signs $900m cancer and infectious disease deal with Nykode
Along with its new name, Nykode has announced its deal with Regeneron that is worth up to $900m. ... The collaboration with Regeneron covers multiple targets across five programmes, two focused on vaccines against infectious disease and three against
EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
This includes Lilly’s bamlanivimab and etesevimab combination, Roche and Regeneron’s REGEN-COV (casirivimab and imdevimab), Celltrion’s regdanivimab and GlaxoSmithKline/Vir Biotech’s sotrovimab.
US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns
The HHS also said, however, that antibody treatments from Regeneron (REGEN-COV) and GlaxoSmithKline (GSK) and Vir Biotechnology (sotrovimab) are ‘likely’ to be effective against these variants.
Merck’s Keytruda improves outcomes for metastatic cervical cancer patients
In March, Sanofi and Regeneron revealed positive data for their PD-1 inhibitor Libtayo (cemiplimab) in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- MHRA approves second COVID-19 antibody treatment
- Roche acquires test maker TIB Molbiol
- Sanofi to buy acne specialist Origimm
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen hands out $120m upfront for Remedy stroke drug
- Pfizer's 2021 revenue predictions soar to $82bn
- The Pharma Multi-channel Marketing Maturity Model
- Assessing the value of interim analyses in clinical trials
- Booster plans expanded to combat Omicron
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
